Accretion Pharmaceuticals Peer Comparison
NSE: ACCPL
₹199.55
₹0.00 (0.00%)As on 28-Aug-2026 11:38IST
Market cap
₹222 Cr
Revenue (TTM)
₹90 Cr
P/E Ratio
22.9
P/B Ratio
4.3
Div. Yield
0 %
Edit
| Accretion Pharmaceuticals | Acutaas Chemicals | Alembic Pharma | Cohance Lifesciences | Granules India | Onesource Specialty Pharma | Piramal Pharma | Rubicon Research | Syngene Intl | Wockhardt | |
|---|---|---|---|---|---|---|---|---|---|---|
Market cap (₹ Cr) |
222 | 26,871 | 16,000 | 17,242 | 20,739 | 17,579 | 29,103 | 29,892 | 16,284 | 32,104 |
Revenue (₹ Cr) |
90 | 1,462 | 7,784 | 2,142 | 5,632 | 1,543 | 9,205 | 1,936 | 3,600 | 3,564 |
Net Profit (₹ Cr) |
9.67 | 387.35 | 688.47 | 58.53 | 662.35 | -48.62 | -371.81 | 288.22 | 221.00 | 414.00 |
Net Margin (%) |
10.76 | 26.01 | 8.77 | 2.69 | 11.75 | -3.12 | -3.93 | 14.79 | 6.01 | 11.23 |
RoE (%) |
28.72 | 25.18 | 14.02 | 3.29 | 14.34 | -0.61 | -3.85 | 29.77 | 5.62 | 8.38 |
Price to Earnings |
22.94 | 69.57 | 23.07 | 162.31 | 31.31 | -- | -- | 103.71 | 73.68 | 78.49 |
Price-To-Book |
4.25 | 15.55 | 2.74 | 4.48 | 4.23 | 3.00 | 3.64 | 22.27 | 3.44 | 6.38 |
Income Statement (₹ Cr)
| Accretion Pharmaceuticals | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Operating Revenue
|
89.63 | 3,373.00 | 1,753.96 | 8,869.08 | -- |
|
Total Income
|
89.82 | 3,510.00 | 1,762.66 | 9,111.51 | -- |
|
Total Expenditure
|
74.65 | 2,747.00 | 1,354.69 | 7,976.59 | -- |
|
EBITDA
|
14.97 | 626.00 | 399.26 | 892.49 | -- |
|
Depreciation
|
1.21 | 227.00 | 45.26 | 831.24 | -- |
|
EBIT
|
13.76 | 399.00 | 354.00 | 61.25 | -- |
|
Interest
|
0.87 | 213.00 | 42.17 | 340.80 | -- |
|
Other Income
|
0.19 | 137.00 | 8.70 | 242.43 | -- |
|
Exceptional Items
|
-- | -85.00 | -- | -196.14 | -- |
|
Profit before Tax
|
13.08 | 238.00 | 320.53 | -176.06 | -- |
|
Provision for Tax
|
3.42 | 39.00 | 73.80 | 149.88 | -- |
|
Profit after Tax
|
9.67 | 199.00 | 246.74 | -325.94 | -- |
Liabilities (₹ Cr)
| Accretion Pharmaceuticals | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
54.71 | 4,940.00 | 1,288.82 | 8,162.62 | -- |
|
Minority Interest
|
-- | 341.00 | 0.00 | -- | -- |
|
Non-Current Liabilities
|
1.13 | 1,235.00 | 189.02 | 4,529.41 | -- |
|
Current Liabilities
|
20.84 | 1,622.00 | 835.87 | 4,874.74 | -- |
|
Total Liabilities
|
76.68 | 8,578.00 | 2,326.71 | 17,723.32 | -- |
Assets (₹ Cr)
| Accretion Pharmaceuticals | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
13.72 | 5,441.00 | 631.90 | 10,258.66 | -- |
|
Current Assets
|
60.40 | 2,606.00 | 1,681.81 | 7,308.11 | -- |
|
Total Assets
|
76.68 | 8,578.00 | 2,326.71 | 17,723.32 | -- |
|
Total Debt*
|
12.32 | 2,125.00 | 259.37 | 5,495.48 | -- |
|
Net Current Assets
|
39.56 | 984.00 | 845.94 | 2,433.37 | -- |
|
Contingent Liabilities
|
-- | 768.26 | 19.09 | 95.72 | -- |
Cashflow (₹ Cr)
| Accretion Pharmaceuticals | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-14.53 | 390.00 | 205.05 | 1,652.60 | -- |
|
Cash Flow from Investing Activities
|
-8.53 | -241.00 | -409.72 | -826.03 | -- |
|
Cash from Financing Activities
|
27.04 | -54.00 | 283.07 | -38.98 | -- |
|
Net Cash Inflow / Outflow
|
3.97 | 95.00 | 78.39 | 787.59 | -- |
Ratios
Profitability Ratios
| Accretion Pharmaceuticals | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
ROCE (%)
|
29.77 | 6.79 | 29.22 | 1.24 | -- |
|
ROE (%)
|
28.72 | 4.29 | 27.84 | -4.04 | -- |
|
ROA (%)
|
16.59 | 2.53 | 13.11 | -1.98 | -- |
|
EBIT Margin (%)
|
16.92 | 22.62 | 23.26 | 12.80 | -- |
|
Net Margin (%)
|
10.76 | 5.67 | 14.00 | -3.58 | -- |
|
Cash Profit Margin (%)
|
12.14 | 10.98 | 7.71 | 4.80 | -- |
Growth Ratios
| Accretion Pharmaceuticals | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
56.21 | 11.99 | 36.57 | -3.08 | -- |
|
EBIT Growth (%)
|
26.62 | 67.69 | 52.29 | -28.15 | -- |
|
Net Profit Growth (%)
|
42.31 | 449.12 | 83.64 | -457.66 | -- |
|
EPS Growth (%)
|
4.59 | 553.20 | 71.44 | -456.91 | -- |
|
Book Value Growth (%)
|
243.37 | 13.47 | 144.31 | 0.33 | -- |
Valuation Ratios
| Accretion Pharmaceuticals | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Price / Earnings
|
7.31 | 89.54 | 51.69 | 0.00 | -- |
|
Price / Book Value
|
1.35 | 3.87 | 10.14 | 2.24 | -- |
|
Dividend Yield (%)
|
0.00 | 0.00 | 0.19 | 0.00 | -- |
|
EV/EBITDA
|
5.21 | 27.45 | 31.05 | 19.72 | -- |
|
Market Cap (₹ Cr)
|
70.64 | 19,071.62 | 12,753.19 | 18,108.89 | -- |
Solvency Ratios
| Accretion Pharmaceuticals | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.24 | 0.43 | 0.21 | 0.68 | -- |
|
Short term debt to equity ratio
|
0.16 | 0.09 | 0.05 | 0.09 | -- |
|
Current Ratio
|
2.90 | 1.61 | 2.01 | 1.50 | -- |
|
Quick Ratio
|
1.54 | 1.06 | 1.14 | 0.87 | -- |
|
Interest Coverage
|
16.03 | 2.12 | 8.60 | 0.48 | -- |
Operating Efficiency Ratios
| Accretion Pharmaceuticals | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
24.99 | 17.43 | 29.00 | 24.33 | -- |
|
Asset Turnover
|
1.54 | 0.49 | 2.01 | 0.64 | -- |
|
Receivable days
|
69.36 | 58.75 | 40.13 | 78.20 | -- |
|
Inventory Days
|
99.74 | 75.82 | 60.29 | 93.30 | -- |
|
Payable days
|
37.40 | 186.21 | 232.47 | 226.14 | -- |
|
Cash Conversion Cycle
|
131.70 | -51.64 | -132.04 | -54.64 | -- |
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
